Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Current Deferred Revenue (2018 - 2024)

Dna X's Current Deferred Revenue history spans 7 years, with the latest figure at $12000.0 for Q2 2024.

  • Quarterly results put Current Deferred Revenue at $12000.0 for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $12000.0 (changed N/A YoY), and the annual figure for FY2023 was $12000.0, down 61.29%.
  • Current Deferred Revenue for Q2 2024 was $12000.0 at Dna X, roughly flat from $12000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $872000.0 in Q2 2021 to a low of $3000.0 in Q1 2023.
  • The 5-year median for Current Deferred Revenue is $31000.0 (2022), against an average of $166933.3.
  • The sharpest move saw Current Deferred Revenue crashed 98.28% in 2020, then surged 300.0% in 2024.
  • Year by year, Current Deferred Revenue stood at $5000.0 in 2020, then surged by 120.0% to $11000.0 in 2021, then surged by 181.82% to $31000.0 in 2022, then plummeted by 61.29% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $12000.0, $12000.0, and $12000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.